Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
OPPORTUNITIES
IN KOREA
BIOPHARMACEUTICAL
R1
CH
HO
R2
OH
INVESTMENT
OPPORTUNITIES
IN KOREA
BIOPHARMACEUTICAL
KOREA,
Where Success Knows No Limits
Contents
04
Industry overview
Biotech industry
10
18
22
Cost
24
Success cases
28
05
01 INDUSTRY OVERVIEW
INDUSTRY
OVERVIEW
The pharmaceutical
industry
Koreas pharmaceutical market stood at KRW 19.291 trillion (USD 17.3 billion)* in 2013, up 0.3%
YoY, and posted a five-year CAGR of 2.3% from 2008 to 2013. Given that the market recorded
a higher growth rate than the global market until 2010, its growth pace has slowed. However,
Koreas pharmaceutical market continues on a steady growth path despite the global economic
crisis.
In particular, it is notable that Koreas pharmaceutical production increased by 4.1% YoY,
to KRW 16.2 trillion, in 2013, departing from a stagnant growth trend since 2010. Koreas
pharmaceutical exports posted a 2008 - 2013 CAGR of 13% driven by Korean pharmaceutical
companies with a growing presence in the global market.
In contrast, Koreas pharmaceutical imports dropped 10% YoY, to KRW 5.2 trillion in 2013,
contributing to a sharp decline in trade deficits.
In a nut shell, Koreas pharmaceutical industry records modest growth across the board. As
Korean pharmaceutical companies have steadily sharpened their competitiveness, the Korean
industry has increased exports and production volumes and fast reduced trade deficits.
Koreas pharmaceutical industry employed 78,259 individuals in 2013, up 5.1% YoY, or 3,782
individuals. This marks an upturn in pharmaceutical employment, breaking from a downward
trend since 2010, and indicates that business activities have recently gained momentum in
Koreas pharmaceutical industry.
Recent developments in Koreas pharmaceutical industry
Production
2008
2009
2010
2011
2012
2013
% YoY
A 5-year
CAGR
13,893,810
14,788,387
15,569,588
15,440,251
15,560,663
16,191,845
4.1%
3.1%
Export
1,255,891
1,772,242
1,770,059
1,943,493
2,309,534
2,318,522
0.4%
13.0%
Import
4,319,756
4,953,881
5,108,911
5,447,053
5,728,874
5,155,829
-10.0%
3.6%
Trade
balance
-3,063,865
-3,181,639
-3,338,852
-3,503,560
-3,419,340
-2,837,308
-17.0%
-1.5%
Market size
16,957,675
17,970,026
18,908,439
18,943,812
18,980,003
19,029,152
0.3%
2.3%
* Source: Korea Health Industry Development Institute (2014), Analysis of Koreas Pharmaceutical Industry (2013)
06
BIOPHARMACEUTICAL
Pharmaceutical researchers numbered 5,437, accounting for 6.9% of the total workforce in
Koreas pharmaceutical industry. As much as 70.2% of researchers have masters or doctoral
degrees and the research workforce structure was based mostly on higher-skilled talent.
Number of people employed in Koreas pharmaceutical industry
82,000
07
01 INDUSTRY OVERVIEW
Biotech
industry
The biotech industry uses biotechnologies based on DNA, protein and cells to produce various
products, such as biopharmaceuticals, and to create value-added services. The industry includes
biopharmaceuticals, bioengineered food, biochemicals and bio-environment, bioelectronics,
bio-process and device, bio-energy resources, others such as biological assay (assessment) and
bioinformatics services.
Koreas biotech industry stood at KRW 7.52 trillion in 2013, up 5.3% YoY, in terms of domestic
sales and exports, and posted a high CAGR of 8.9% from 2009 to 2013.
81,204
80,000
78,259
78,000
76,000
In terms of production value, the bioengineered food segment is the largest contributor, with
annual production of KRW 3.21 trillion in 2013, accounting for 40% of the biotech industry. The
second-largest contributor is biopharmaceuticals, with annual production of KRW 2.78 trillion.
Biochemicals and other biotech segments are small in terms of absolute production value but
expand at a fast pace, raising expectations that they will represent an increasing share of the
biotech industrys production.
77,314
75,406
74,477
74,000
72,000
70,000
2008
2009
2010
2011
2012
* Source: Korea Health Industry Development Institute (2014), Analysis of Koreas Pharmaceutical Industry (2013)
Year
(Unit: People)
2009
2010
Others
107
2011
Ph.D. holders
637
B.S. degree
holders
1,509
2012
2013
% YoY
M.S. degree
holders
3,184
* Source: Korea Health Industry Development Institute (2014), Analysis of Koreas Pharmaceutical Industry (2013)
Production
Total
Biopharmaceuticals
Biochemicals
Bioengineered food
Other
Domestic sales
2,907,448
1,564,251
260,356
283,954
601,718
Export
2,728,749
1,209,223
69,907
722,474
371,403
Domestic sales
3,346,287
1,521,210
230,073
989,797
605,207
Export
2,441,539
852,028
60,352
1,356,334
172,825
Domestic sales
3,646,896
1,506,329
355,684
1,065,834
719,049
Export
2,749,356
954,412
74,783
1,531,965
188,195
Domestic sales
4,068,644
1,577,572
408,226
1,261,325
821,521
Export
3,060,585
1,139,980
97,173
1,610,631
212,802
Domestic sales
4,357,396
1,636,942
451,091
1,338,933
930,430
Export
3,166,435
1,138,462
111,110
1,682,131
234,731
Domestic sales
7.10%
3.76%
10.50%
6.15%
13.26%
Export
3.46%
-0.13%
14.34%
4.44%
10.30%
10.64%
1.14%
14.73%
47.36%
11.51%
3.79%
-1.50%
12.28%
23.53%
-10.84%
Domestic sales
CAGR
(2009 - 2013) Export
The domestic biotech market stood at KRW 5.87 trillion in 2013, up 6.1% YoY, posting a CAGR of
8.5% from 2009 to 2013.
By segment, the biochemicals segment posted the fastest growth, at 8.5% YoY. Of other
biotech segments, the bioelectronics and bio-environment segments recorded a high growth
rate of 53.8% YoY and 9.6% YoY, respectively, although their domestic sales were relatively low,
at KRW 37.3 billion and KRW 30.3 billion.
08
BIOPHARMACEUTICAL
09
01 INDUSTRY OVERVIEW
In terms of domestic sales, biopharmaceuticals are the largest segment, accounting for 50%
of the biotech market. However, biopharmaceuticals record a slower growth rate than other
segments, while bioengineered food and biochemicals marked higher growth rates. The biotech
market is expected to grow beyond biopharmaceuticals to include diverse segments such as
biochemical, bioengineered food and other biotech segments.
913
958 971
2011
2012
2013
800
700
600
2010
2011
2012
2013
500
CGAR
% YoY
(2009 - 2013)
400
Total
4,236,695
4,751,946
5,208,078
5,643,437
5,866,853
3.96%
8.48%
300
Biopharmaceuticals
2,536,348
2,620,986
2,736,657
2,819,494
2,961,578
5.04%
3.95%
200
Biochemicals
372,034
324,505
435,402
476,952
515,177
8.01%
8.48%
100
Bioengineered food
317,692
999,180
1,098,907
1,320,973
1,385,571
4.89%
44.51%
Other
813,452
807,273
937,112
1,026,018
1,004,527
-2.09%
5.42%
The number of companies in Koreas biotech industry increased by 13, from 958 in 2011 to 971 in
2012, marking an upward trend.
By segment, the number of biotech companies increased in the biopharmaceuticals,
biochemicals and other segments but slightly declined in the bioengineered food segment.
276
188
Total
The number of researchers amounted to 11,605 individuals, or 30.4% of the employees in Koreas
biotech industry. About 60% of researchers have masters or doctoral degrees. The workforce is
highly skilled in the biotech industry, as seen in the pharmaceutical industry.
Biopharmaceuticals
204 203
Biochemicals
Bioengineered food
Other
In 2013, the number of people employed by biotech companies stood at 38,197, marking an
increase of 627 individuals from 2012. In other words, the average number of employees per
biotech firm stood at 39.3.
305 317
Biochemicals
Bioengineered food
Other
Total
* Source: Biotech Industry Study (2014)
People
Doctoral degree
Other
Share (%)
People
People
People
People
18,469
1,030
3,519
6,877
7,043
100%
6%
19%
37%
38%
4,936
362
1,355
1,937
1,282
100%
7%
27%
39%
26%
8,070
345
1,298
3,527
2,900
100%
4%
16%
44%
36%
6,722
359
1,239
3,079
2,045
100%
5.34%
18.43%
45.80%
30.42%
38,197
2,096
7,411
15,420
1,285
100%
5.49%
19.40%
40.37%
3.36%
10
BIOPHARMACEUTICAL
Global market
outlook
11
The global pharmaceutical and biotech markets have steadily expanded thanks to an aging
population and growing awareness of healthy lifestyles worldwide.
The global pharmaceutical industry expanded 2.4% YoY, to USD 959 billion in 2012, and posted
a high CAGR of 5.3% from 2007 to 2012. The growth rates are relatively low compared to the
pre-crisis growth rate of about 8%. However, the global pharmaceutical industry has continued
on a steady growth path despite a global economic slowdown, as national healthcare spending
and demand for healthcare have increased amid aging populations in Asia.
The global biotech market amounted to USD 1.18 trillion in 2012. This global industry is one of the
most promising and expected to reach USD 1.57 trillion in 2015, with a 2010 - 2015 CAGR of 9.7%.
Size and growth outlook of the global biotech market
Year
CAGR
2010
987.2
9.1%
9.7%
2011
1,079.0
9.3%
9.7%
2012
1,181.5
9.5%
9.7%
2013
1,298.4
9.9%
9.7%
2014
1,434.7
10.5%
9.7%
2015
1,572.4
9.6%
9.7%
COMPETITIVE
STANDING
AND OUTLOOK
Future
development
of pharmaceutical and
biotech
industries
The future development of the pharmaceutical and biotech industries is expected to be led by
technology convergence-driven new industries, such as BIT.
The ubiquitous healthcare industry has emerged thanks to IT-related innovative technologies,
creating new medical device markets such as portable diagnostic devices for remote health
monitoring, remote consultation and remote treatment. The personalized healthcare market is
estimated to reach USD 63.9 billion in 2015, from USD 33.7 billion in 2010.
Thanks to dramatic technological developments in DNA analysis, key product categories will
include chips and diagnosis kits based on DNA sequencing and protein analysis.
The preventive medicine segment, such as the introduction of biosensors and biomarkers, is
expected to develop thanks to growing demand for products that enable fast diagnosis and
early detection, for disease prevention. The development of personalized target therapy and
companion biomarkers (companion diagnostics) are expected to emerge as a new business
model for the pharmaceutical industry.
12
BIOPHARMACEUTICAL
The industry shift from one-size-fits-all products to personalized treatment products should be
accelerated.
M edicinal treatment and management will take into consideration personal genetic
information and physical traits, departing from the practice of applying the same treatment
to all patients. In this regard, development of the single-nucleotide mutation search, precision
diagnosis and monitoring segments will enable drug response prediction and help establish a
system to fend off trial and error and side effects in advance.
13
14
BIOPHARMACEUTICAL
15
New drug
Development stage
Celltrion
Celltrion
Dong-A ST
LG Life Sciences
Pharmicell
Medipost
Antrogen
Core Stem
The therapeutic antibodies segment is among the most promising in the pharmaceutical
industry. Koreas therapeutic antibodies market increased from KRW 30 billion in 2006 to KRW 83
billion in 2010. If the domestic development of new therapeutic antibodies speeds up, Koreas
therapeutic antibodies segment will reach KRW 300 billion in 2015.
ISU ABXIS recorded KRW 3.3 billion in sales with Clotinab, Koreas first antibody-based
treatment. Celltrion has actively conducted R&D in therapeutic antibodies, winning approvals
for its infliximab biosimilar Remsima and completing the phase III clinical trial of the biosimilar
Herceptine (breast cancer treatment).
Outlook for the Korean therapeutic antibodies market
3,000
3,000
Market size
2,500
R&D investments
800,000
648,362
600,000
1,500
967,239
1,000,000
2,000
1,000
813,755
684,207
500
578,268
830
300
400,000
* Source: Ministry of Trade, Industry & Energy, Five-year Plan for Technology Innovation (2013)
200,000
0
2008
2009
2010
2011
2012
(Unit: %)
Given that Korea is one of the countries with the most rapidly aging population, the outlook
for demand in the biotech industry is positive. In addition, the biotech industry is expected
to continue on a growth path driven by government support and the commitment of large
corporations to new business development.
9,00
R&D concentration rate
8,00
7,00
6,00
5,00
6.24
6.50
6.44
2008
2009
2010
7.41
7.67
2011
2012
4,00
3,00
2,00
1,00
0,00
Accordingly, Korean companies increase their R&D investments to secure their competitiveness
in the biotech industry. Koreas biotech R&D investments reached KRW 1.165 trillion in 2013,
continuing on a growth path.
Korea ranks fifth among OECD member countries, following the United States, France, Japan
and Germany in terms of the private sectors investments in the biotech segment. In addition,
the biotech segment accounts for 20% of the Korean governments investments, the second
largest among OECD member countries, following Germany.
Statistics show that the Korean government has played a key role in establishing the scientific
foundation for biotech research. The public sectors efforts have facilitated the private sectors
investments and put the biotech industry on the path to growth and development.
16
BIOPHARMACEUTICAL
10,000
8,000
9,302
R&D investments
8,761
9,988
7,686
7,293
6,000
4,000
2,000
0
2008
2009
2010
2011
2012
Major companies
Biopharmaceuticals
Biochemicals
Bioengineered food
Other
The in vitro diagnostic segment is expected to be among the fast-growing markets of the biotech
industry. The segment has strong growth potential thanks to new technology development and
a rapidly aging population. The market is estimated to reach KRW 420 billion in 2014.
Koreas in vitro diagnostic medical device (IVDs) market
2009
Bioelectronics
Bioinformatics & biological assay
Bio diagnostics
(20% of the diagnostic test market)
Total
2010
2011
2012
2013
2014
369
489
553
624
724
840
1,406
1,355
1,531
1,730
1,955
2,209
600
690
780
881
996
1,125
2,375
2,534
2,864
3,235
3,675
4,174
* Source: Ministry of Trade, Industry & Energy, Five-year Plan for Technology Innovation (2013)
In particular, the bio-convergence segment has strong growth potential thanks to Koreas
17
In this regard, the development of bio chips has been led by public research institutes and
universities such as the Korea Institute of Science & Technology (KIST), Electronics and
Telecommunications Research Institute (ETRI), Korea Electronics Technology Institute (KETI),
Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and
Technology (POSTECH), Seoul National University (SNU) and private research institutes and
large corporations such as Samsung Advanced Institute of Technology (SAIT), LG Electronics
Tech Center and LG Chem. Recently, an increasing number of biotech startups have been
entering the market.
Of Koreas IVD market, companies such as HBI, SD, Humasis, Bio Focus, Nano EnTek and K-MAC
are new entrants in the immune segment, and companies such as Seegene and Bioneer have
DNA diagnosis products and globally competitive technologies in the molecular diagnosis
segment.
In addition, as the focus of healthcare has shifted from treatment to disease prevention due to
an aging population, the personalized healthcare market is expected to fast expand, enabling
routine and customized health care through early diagnosis, a ubiquitous healthcare system
and personal health records.
18
BIOPHARMACEUTICAL
GOVERNMENT
POLICIES AND
RELATED
REGULATIONS
Government
policies by
industry
19
20
BIOPHARMACEUTICAL
To increase awareness of Koreas pharmaceutical products in the global market, the Korean
government has assisted Korean companies in their expansion to new emerging markets,
enhancing government-to-government collaboration and sending private-public market
development delegations. During Bio Korea 2013 (September 11-13, 2013), Pharm Fair was held
on the sidelines to bring together related foreign authorities in the drug approval segment and
promote marketing cooperation with overseas drug distribution companies. Pharm Fair created
an opportunity for Korean pharmaceutical companies to generate businesses worth KRW 170
billion, including the USD 100 million export deal between BC World Pharm and KOA SHOJI
(Japan). Such policy efforts should help Korean companies look beyond the domestic market,
reach out to the rest of the world and become globally competitive players.
The Korean government introduced a pilot procedure combining drug approval and price
evaluation from October to December of 2013, to shorten the time-to-market for new drugs
and the evaluation period of drug list prices and thus establish an efficient infrastructure for new
drug development.
2009
2010
2011
CAGR
123,437
137,014
148,902
9.8%
Biotech R&D
20,112
23,252
25,808
13.3%
16.3%
17.0%
17.3%
Government R&D
21
The Korean government announced in July of 2013 the Government-wide Mid- to Long-term
Action Plans to Promote R&D for National Healthcare, integrating policy plans established
by ministries responsible for the biotech and healthcare industries. Moreover, the Korean
government seeks to increase public investments and ease investment restrictions in an effort to
promote private investments.
As part of a private-public initiative to promote the biochemicals sector, a total of KRW 250
billion will be invested for a five-year period from 2013. The Korean government is also making
efforts to establish a full-cycle R&D system through collaboration with related companies and to
overhaul the system, which requires that public organizations prioritize the purchase of certain
products upon procurement. As such, various mid- to long-term initiatives are underway to
ensure Korea will be among the top five in the global biochemicals market by 2020.
The Ministry of Trade, Industry & Energy has launched a five-year biochemicals technology
development project worth KRW 215.5 billion in 2014 with the goal of accelerating the
development of technology and production infrastructure.
22
COST
BIOPHARMACEUTICAL
23
04 COST
The average annual salary at Korean pharmaceutical companies is USD 27,681, with the top 25%
at USD 42,987 and the bottom 25% at USD 15,903. The starting salary at major companies tends
to be higher at multinational companies than Korean companies and is distributed as follows.
Starting salary at major pharmaceutical companies
(Unit: USD)
Company
GlaxoSmithKline
33,393
Korea Polyol
32,491
AstraZeneca Korea
31,769
Pfizer Korea
31,588
ISU Chemical
30,505
Dong-A Pharm
29,874
Yuhan Corporation
27,076
Dongwoo Fine-Chem
24,368
40,000
Average salary
35,000
32,139
28,384
30,000
25,000
(Unit: USD)
22,572
20,000
15,000
10,000
5,000
0
Ph.D. holders
24
BIOPHARMACEUTICAL
05 SUCCESS CASES
SUCCESS CASES
25
1) Celltrion: KRW 350 billion in investments from Temasek, Singapores sovereign wealth fund,
since 2010
Celltrion attracted KRW 207.9 billion in investments from Temasek, Singapores sovereign wealth
fund, in 2010 thanks to its superb biosimilar technologies and solid contract manufacturing
organization (CMO) business. Temasek acquired a 10% stake in Celltrion Healthcare, Celltrions
affiliate, and made an additional investment of about KRW 150 billion in 2013.
Investment incentives and outcomes
Celltrion has expanded the global market coverage of Remsima, a biosimilar version of
Remicade (rheumatoid arthritis drug), winning regulatory approvals in Korea and Europe. With
the completion of a phase 3 clinical trial of the biosimilar Herceptine (breast cancer treatment),
the company has made significant achievements in the biosimilar segment.
It was biosimilar capability that enabled Celltrion to attract foreign investments. Foreign
investments helped Celltrion repay its debts, raise operating capital, enhance its presence in
the global capital market and place a greater focus on developing biosimilar and therapeutic
antibody technologies.
2) Aprogen: Strategic partnership with Japans Nichi-Iko Pharmaceutical (2010) and exclusive
sales right worth KRW 30 billion (2014)
Aprogen, a tech venture in the Daeduk Specialized Zone, attracted an investment of KRW
13.3 billion in the biosimilar business from Japans Nichi-Iko Pharmaceutical in 2010. Nichi-Iko
Pharmaceutical acquired a 33.4% stake in Aprogen and entered into an agreement to conduct
clinical trials, file for regulatory approval and sell Aprogens biosimilars in Japan. Afterwards,
Aprogen developed the Remicade biosimilar and entered into an exclusive supply contract
with Nichi-Iko Pharmaceutical for KRW 30 billion in 2014.
Investment incentives and outcomes
Aprogen is a subsidiary of Schnell Biopharmaceuticals and the first company in Korea to have
promoted the development of new drugs based on protein and antibodies. Aprogen was
established in 2000 by two professors from the Korea Research Institute of Bioscience and
Biotechnology (KRIBB) and KAIST and has transferred four biosimilar drug technologies to
other companies. Currently, the company is developing four kinds of biosimilars and three
kinds of protein-based new drugs. In addition, the company transferred its business right to
biosimilars of Ramicade (rheumatoid arthritis treatment) and Rituxan (anti-cancer drug) to
Schnell Biopharmaceuticals.
Aprogen attracted equity investments from Japans Nichi-Iko Pharmaceutical in 2010 to finance
its biosimilar production and facilitate its advancement in the global market. The agreement
in 2014 includes an investment clause that Nichi-Iko Pharmaceutical will provide capital for
Aprogen to build large-scale biosimilar production facilities. As such, Aprogen has secured
financing for its production facilities and an exclusive right to supply products.
26
BIOPHARMACEUTICAL
3) Samsung BioLogics: Joint venture between Samsung and Quintiles Transnational Corp.
Samsung BioLogics has created a USD 300 million biosimilar development JV with Biogen Idec.
Samsung and Quintiles Transnational Corp, a U.S.-based global clinical research service
provider, established Samsung BioLogics, a joint venture with KRW 300 billion in capital.
BioLogics teamed up with Biogen Idec to establish a joint venture that develops, manufactures
and sells biosimilars. Samsung BioLogics started construction of a biopharmaceutical plant
with a cell culture capacity of 30,000 liters in June of 2011, with plans to complete the pilot
production of therapeutic antibodies in August of 2014 and start mass production in 2015.
Investment incentives and outcomes
Samsung BioLogics has secured access to the global biotech industry by attracting foreign
investment. In addition, Samsung BioLogics is well-positioned to sharpen its competitiveness
in the biopharmaceutical segment, as it can share knowhow with a global company in
various areas such as contract manufacturing and preclinical and clinical trials. In addition,
the establishment of mass production facilities for biosimilars should allow the company to
expand biopharmaceuticals production, extend global market reach and accelerate R&D.
4) Dong-A Pharm: Strategic partnership with GSK
In May of 2010, Dong-A Pharm forged a strategic partnership with the global pharmaceutical
company Glaxo Smith Kline (GSK). GSK acquired a 9.9% stake in Dong-A Pharm to jointly
operate the sales, clinical trials and commercialization of ethical drugs. It is a comprehensive
partnership that enables Dong-A Pharm to secure a stable supply of GSKs key pipeline drugs
and GSK to use Dong-A Pharms sales networks and marketing force in Korea. GSK and Dong-A
Pharm expanded their partnerships in March of 2012 to include over-the-counter (OTC) drugs,
generating synergy effects both in the OTC and ethical drug markets.
Investment incentives and outcomes
The partnership between GSK and Dong-A Pharm is an unprecedented model of partnership
between a global pharmaceutical company and a Korean pharmaceutical company. In
particular, GSK has identified Korea as an attractive investment destination, given Koreas
R&D capacity and clinical trial experiences, and thus showed great interest in Dong-A Pharms
overseas R&D pipeline. Through partnerships, Dong-A Pharm has secured an opportunity to
learn global clinical expertise and successfully expand its global business.
05 SUCCESS CASES
27
28
BIOPHARMACEUTICAL
Related associations
RELATED
COMPANIES AND
ASSOCIATIONS
Name
Website
blog.naver.com/kbda0711
www.knrea.or.kr
cafe.naver.com/ilovepellet
www.kbpa.net
www.biopack.or.kr
www.kagh.co.kr
www.kha.or.kr
www.kpanet.or.kr
www.komedia.or.kr
www.kma.org
www.uha.or.kr
www.kahp.or.kr
KoreaInternational MedicalAssociation
www.koreahealthtour.co.kr
www.kgha.kr
www.ko-bia.or.kr
www.koreabio.org
www.kbra.or.kr
www.kobsa.net
www.kdra.or.kr
www.medinet.or.kr
www.kmdia.or.kr
www.kapw.or.kr
www.kpta.or.kr
www.kpma.or.kr
www.kfia.or.kr
www.koreacpa.org
www.kosaseed.or.kr
www.kahpa.or.kr
www.kvma.or.kr
www.kaff.or.kr
www.aiak.or.kr
29
30
BIOPHARMACEUTICAL
Related companies
Company
Website
Seoul Pharma
www.seoulpharma.com
Suheung
www.suheung.com
Hutecs Pharmaceutical
www.hutecs.co.kr
SS Pharm
www.susungpharm.com
www.ahn-gook.com
RP Corp
www.rpskorea.com
PharmbioKorea
www.pharmbio.co.kr
SB Pharmaceutical
www.sbp.com
Company
Website
Gwangdong Pharmaceutical
www.ekdp.com
Kukje Pharm
www.kukjepharm.co.kr
Green Pharm
BC World Pharm
www.bcwp.co.kr
Kunwha Pharmaceutical
www.kunwha.com
GlaxoSmithKline
www.gskkorea.co.kr
Green Cross
www.greencross.com
Daelim Pharmaceutical
SK Chemicals
www.skchemicals.com
Daewoong Pharmaceutical
www.daewoong.co.kr
Estech Pharma
www.estechpharma.com
Daewon Pharm
www.daewonpharm.com
Dream Pharm
www.dreampharma.co.kr
JW-Shinyak
www.jw-shinyak.co.kr
Nensys
www.nensys.co.kr
www.daihan.com
LG Life Sciences
www.lgls.co.kr
Daehwa Pharmaceutical
www.dhpharm.co.kr
YD Diagnostics
www.yd-diagnostics.com
Dongkook Pharmaceutical
www.dkpharm.co.kr
Yungjin Pharmaceutical
www.yungjin.co.kr
Huniz
www.huniz.kr
Youyoung Pharmaceutical
www.yypharm.co.kr
Dong-A Pharm
www.donga.co.kr
Yuyu Pharma
www.yuyu.co.kr
www.dong-wha.co.kr
UK Chemi Pharm
www.ukchemipharm.co.kr
Mundi Pharma
mundipharma.co.kr
Bioland
www.biolandkorea.com
Medica Korea
www.medicakorea.com
Yuhanmedica
www.yuhanmedica.co.kr
BiNex
www.bi-nex.com
Yuhan Corporation
www.yuhan.co.kr
Baxter
www.baxter.co.kr
Ildong Pharmaceutical
www.ildong.com
Bolak
www.bolak.co.kr
Ilsung Pharmaceutical
www.ilsung-ph.co.kr
Boryung Pharm
www.boryung.co.kr
ILYANG Pharmaceutical
www.ilyang.co.kr
Sewon Cellontech
www.sewoncellontech.com
Ilhwa
www.ilhwa.co.kr
B. Braun Korea
www.bbraun.co.kr
JRP
www.jrpharm.co.kr
Bukwang Pharm
www.bukwang.co.kr
www.kyowa-kirin-korea.com
Samnam Pharm
www.samnam51.com
Jeil Pharmaceutical
www.jeilpharm.co.kr
www.sfc.samsung.co.kr
Choa Pharmaceutical
www.choa.co.kr
Sama Pharm
www.samapharm.co.kr
www.ckdpharm.com
Samyang Biopharmaceuticals
www.samyangpharm.co.kr
JW Pharmaceutical
www.cwp.co.kr
www.samyangchem.com
Jinyang Pharm
www.jinyangpharm.com
Samil Pharm
www.samil-pharm.co.kr
Unimed Pharm
www.unimed.co.kr
Samjin Pharm
www.samjinpharm.co.kr
Chunggei Pharm
www.chunggei.co.kr
www.scd.co.kr
Chodang Pharm
www.chodang.com
Saehan Pharm
www.shpharm.co.kr
KMS Pharm
www.kmspharm.com
31
32
BIOPHARMACEUTICAL
Company
Website
Company
Website
Kolon Pharm
www.kolonpharm.co.kr
www.astellas.com/kr
Pharmicell
www.pharmicell.com
Handok Pharm
www.handok.co.kr
www.taiguk.co.kr
Hanmi Pharm
www.hanmi.co.kr
Pharma King
www.pharmaking.co.kr
Hanbul Pharm
www.hanbulpharm.co.kr
Taejoon Pharm
www.taejoon.co.kr
Celltrion
www.celltrionph.com
Pacific Pharm
www.pacificpharm.co.kr
Hanall Biopharma
www.hanall.co.kr
Richwood Pharmaceutical
www.richwood.net
Hanzhung Pharmaceutical
www.hzpharm.co.kr
www.fresenius-kabi.co.kr
Hanpoong Pharm
www.hanpoong.co.kr
Hana Pharm
www.hanaph.co.kr
www.hwpharm.com
Hawon Pharm
www.hawonpharm.co.kr
CMIC CMO
cmic-cmo.co.kr
Nelson Korea
www.nelsonkorea.co.kr
Hyundai Pharm
www.hyundaipharm.co.kr
PMG Pharm
www.pmgpharm.co.kr
Whanin Pharm
www.whanin.com
www.daiichisankyo.co.kr
Huons
www.huons.co.kr
DPH Korea
www.dhpkorea.co.kr
CJ Health Care
www.cjp.co.kr
Korea Vaccine
www.koreavaccine.com
Isu Abxis
www.abxis.com
www.mctt.co.kr
GL Pharm Tech
www.glpt.co.kr
www.hsp.co.kr
MG
www.medi-green.co.kr
Genexine
www.genexine.com
www.bioyd.co.kr
www.arlico.co.kr
www.globalpharm.co.kr
Alcone Korea
www.alconlabs.co.kr
www.swpharm.com
Newgenpharm
www.newgenpharm.com
Mcnulty Pharmaceutical
www.mcnultypharm.com
Janssen Korea
www.janssenkorea.com
Humedix
www.humedix.com
Eisai Korea
www.eisaikorea.com
Donwoo Syntech
dongwookr.com
Otsuka Pharmaceutical
www.otsuka.co.kr
www.samsungbioepis.com
C&R Research
www.cnrres.co.kr
www.whpharma.com
www.kaeri.re.kr
Crystal Genomics
www.crystalgenomics.com
www.kup.co.kr
Bio Leaders
www.bioleaders.co.kr
www.ukp.co.kr
www.medihelpline.co.kr
CTC Bio
www.ctcbio.com
www.kgc.or.kr
www.koruspharm.co.kr
Korea Pharma
www.koreapharma.co.kr
www.pharvis.co.kr
Ferring Pharmaceuticals
www.ferring.co.kr
www.koreaprime.co.kr
33
Invest Korea's
Global Network
Supporting foreign investors worldwide
Headquarters
Address 13, Heolleung-no, Seocho-gu, Seoul, Republic of Korea
Tel (82-2) 1600-7119 Fax (82-2) 3460-7920
E-mail ikonline@kotra.or.kr
Homepage www.investkorea.org
NORTH AMERICA
New York, USA
Tel (212) 826-0900
E-mail kotrany@hotmail.com
Los Angeles, USA
Tel (323) 954-9500
E-mail info@kotrala.com
Chicago, USA
Tel (312) 644-4323
E-mail info@kotrachicago.com
Dallas, USA
Tel (972) 243-9300
E-mail joongik@kotradallas.com
Washington D.C., USA
Tel (202) 857-7919
E-mail washington@kotra.or.kr
Silicon Valley, USA
Tel (408) 432-5000
E-mail info@kotrasv.org
Detroit, USA
Tel (248) 619-1601
E-mail detroit@kotradtt.org
Vancouver, Canada
Tel (604) 683-1820
E-mail ktc@kotrayvr.com
Toronto, Canada
Tel (416) 368-3399
E-mail info@kotra.ca
EUROPE
Frankfurt, Germany
Tel (49-69) 2429-920/9
E-mail frankfurt@kotra.or.kr
Hamburg, Germany
Tel (49-40) 3405-740
E-mail info@kotra.de
Munich, Germany
Tel (49-89) 2424-2630
E-mail munich@kotra.or.kr
Paris, France
Tel (33-1) 5535-8888
E-mail paris@kotra.or.kr
Moscow, Russia
Tel (7-495) 258-1627-8
E-mail info@kotra.ru
London, U.K.
Tel (44-20) 7520-5300
E-mail kotra@kotra.co.uk
Brussels, Belgium
Tel (32-2) 205-0088
E-mail kotrabru@kotra.or.kr
Milan, Italy
Tel (39-02) 79-5813
E-mail kotramil@kotra.it
Zurich, Switzerland
Tel (41-44) 202-1232
E-mail ktc@kotra.ch
Stockholm, Sweden
Tel (46-8) 30-8090
E-mail stockholm@kotra.nu
Copenhagen, Denmark
Tel (45) 3347-7221
E-mail info@kotra.dk
Amsterdam, Netherlands
Tel (31-20) 754-6900
E-mail info@koreatradecenter.nl
Vienna, Austria
Tel (43-1) 586-3876
E-mail kotravie@kotra.at
Madrid, Spain
Tel (34-91) 556-6241
E-mail madridktc@kotra.or.kr
Hangzhou, China
Tel (86-571) 8110-3099
E-mail ljl88@kotra.or.kr
Nanjing, China
Tel (86-025) 8328-8991
E-mail bonkyung@kotra.or.kr
Hong Kong, China
Tel (852) 2545-9500
E-mail kotra5@kotra.org.hk
www.Invest Korea.org
Taipei, Taiwan
Tel (886-2) 2725-2324
E-mail kotra.tpe@msa.hinet.net
Kuala Lumpur, Malaysia
Tel (60-3) 2117-7100
E-mail gunwony@kotra.or.kr
Jakarta, Indonesia
Tel (62-21) 574-1522
E-mail jakarta@kotra.or.kr
Mumbai, India
Tel (91-22) 4925-5400
E-mail ktcmumbai@kotra.or.kr
MIDDLE EAST
You want to do business in Korea but dont know where to start. Where should you turn? Invest Korea.
As the national investment promotion organization of Korea, Invest Korea helps foreign companies
enter the Korean market. It offers a free one-stop service that includes a wide range of pre-investment,
investment and post-investment support, with offices located around the world.
Contact the Invest Korea office nearest you.
KOREA,
Where Success Knows No Limits
www.investkorea.org
13, Heolleung-no, Seocho-gu, Seoul, Republic of Korea (137-749) Tel (82-2)1600-7119 Fax (82-2)3460-7920